Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pleiotropy01:33

Pleiotropy

42.1K
Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
42.1K
Exon Recombination02:32

Exon Recombination

3.9K
The evolution of new genes is critical for speciation. Exon recombination, also known as exon shuffling or domain shuffling, is an important means of new gene formation. It is observed across vertebrates, invertebrates, and in some plants such as potatoes and sunflowers. During exon recombination, exons from the same or different genes recombine and produce new exon-intron combinations, which might evolve into new genes. 
Exon shuffling follows “splice frame rules.” Each exon...
3.9K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

605
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
605
Lethal Alleles02:41

Lethal Alleles

17.3K
Agouti: A Lethal Allele
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...
17.3K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

1.8K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.8K
Human Genetics01:28

Human Genetics

1.1K
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

LINC01234 Coordinates Protein Interactions and ceRNA Networks to Enhance YWHAZ-Driven Malignancy in Triple-Negative Breast Cancer.

Clinical breast cancer·2026
Same author

A straightforward access to specific bisindole systems related to caulersin.

Organic & biomolecular chemistry·2026
Same author

Postoperative anlotinib plus radiotherapy in patients with newly diagnosed, unmethylated O<sup>6</sup>-methylguanine-DNA methyltransferase glioblastoma: A single-arm, phase 2 study.

Cancer·2026
Same author

A Multi-Scale Edge-Preserving Decomposition and Fusion Framework for Multi-Polarization Passive Millimeter-Wave Imaging.

Sensors (Basel, Switzerland)·2026
Same author

Assessing climate-driven treeline dynamics via the habitat suitability index.

Journal of environmental management·2026
Same author

Chikusetsu saponin IVa mitigates septic cardiac injury by targeting DRP1 to suppress mitochondrial damage and NLRP3 inflammasome activation.

Life sciences·2026

Related Experiment Video

Updated: Nov 17, 2025

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

14.0K

The ALOXE3 gene variants from patients with Dravet syndrome decrease gene expression and enzyme activity.

Mei-Mei Gao1, Hao-Ying Huang1, Si-Yu Chen1

  • 1Institute of Neuroscience and the Second Affiliated Hospital of Guangzhou Medical University, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, 250 Changang East Road, Guangzhou, 510260, China.

Brain Research Bulletin
|February 13, 2021
PubMed
Summary

Genetic variants in the ALOXE3 gene, particularly in its promoter region and coding exons, are linked to epilepsy. These ALOXE3 mutations may disrupt the arachidonic acid pathway, offering new diagnostic targets for epilepsy.

Keywords:
ALOXE3Arachidonic acidDravet syndromeGenetic screeningMutation

More Related Videos

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

34.3K
Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information
09:37

Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information

Published on: August 15, 2019

10.1K

Related Experiment Videos

Last Updated: Nov 17, 2025

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

14.0K
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

34.3K
Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information
09:37

Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information

Published on: August 15, 2019

10.1K

Area of Science:

  • Neurogenetics
  • Molecular Biology
  • Epilepsy Research

Background:

  • Epilepsy is a common neurological disorder linked to aberrant gene expression and dysfunction in the brain.
  • Arachidonate lipoxygenase 3 (ALOXE3) plays a role in the arachidonic acid (AA) metabolic pathway, and its overexpression can reduce seizure severity.
  • The direct link between ALOXE3 gene mutations and epilepsy has not been previously established.

Purpose of the Study:

  • To investigate the relationship between ALOXE3 gene mutations and epilepsy.
  • To characterize the promoter region of the human ALOXE3 gene.
  • To identify and functionally assess ALOXE3 variants in patients with Dravet syndrome.

Main Methods:

  • Characterization of the human ALOXE3 promoter using luciferase reporter gene assays in HEK-293 and SH-SY5Y cells.
  • Screening of the ALOXE3 promoter and coding exons for variants in patients with Dravet syndrome.
  • Functional analysis of identified variants, including promoter activity assays and assessment of enzyme activity in cell lines.

Main Results:

  • Five variants in the ALOXE3 promoter (c.-163T>C, c.-50C>G, c.-37G>A, c.+228G>A, c.+290G>T) and one missense variant (c.1939A>G, p.I647V) were identified.
  • The novel promoter variant c.-50C>G, located within a TFII-I binding element, reduced ALOXE3 gene expression by inhibiting TFII-I binding.
  • The p.I647V variant decreased ALOXE3 enzyme activity, impacting cellular arachidonic acid levels.

Conclusions:

  • Identified ALOXE3 variants, including promoter and missense mutations, potentially contribute to epileptogenesis via the arachidonic acid pathway.
  • These findings suggest a novel genetic basis for epilepsy related to ALOXE3 dysfunction.
  • The study provides a new avenue for the clinical diagnosis of epilepsy by identifying ALOXE3 as a potential causative gene.